Table 3.
Comparison of the different models regarding RFS in the training and validation cohorts.
| No. of Variables | Variables included in the model | Brier score | IPA at 1year, % | IPA drop |
|---|---|---|---|---|
| Training cohort | ||||
| 1 (final model) | Rad-score + ΔCA19-9 + Differentiation + Lymph node metastasis + LVI + SMAD4 + Adjuvant therapy | 0.135551151 | 0.305826195 | 0 |
| 2 | ΔCA19-9 + Differentiation + Lymph node metastasis + LVI + SMAD4 + Adjuvant therapy | 0.139392659 | 0.286153371 | 0.019672824 |
| 3 | Rad-score + ΔCA19-9 + Lymph node metastasis + LVI + SMAD4 + Adjuvant therapy | 0.146757759 | 0.248435803 | 0.057390392 |
| 4 | Rad-score + ΔCA19-9 + Differentiation + LVI + SMAD4 + Adjuvant therapy | 0.136588037 | 0.300516179 | 0.005310016 |
| 5 | Rad-score + Differentiation + Lymph node metastasis + LVI + SMAD4 + Adjuvant therapy | 0.144486321 | 0.260068112 | 0.045758083 |
| 6 | Rad-score + ΔCA19-9 + Differentiation + Lymph node metastasis + SMAD4 + Adjuvant therapy | 0.143317882 | 0.26605183 | 0.039774365 |
| 7 | Rad-score + ΔCA19-9 + Differentiation + Lymph node metastasis + LVI + Adjuvant therapy | 0.14245439 | 0.270473875 | 0.03535232 |
| 8 | Rad-score + ΔCA19-9 + Differentiation + Lymph node metastasis + LVI | 0.138483372 | 0.290809936 | 0.015016259 |
| Validation cohort | ||||
| 1 (final model) | Rad-score + ΔCA19-9 + Differentiation + Lymph node metastasis + LVI + SMAD4 + Adjuvant therapy | 0.196208964 | 0.206180219 | 0 |
| 2 | ΔCA19-9 + Differentiation + Lymph node metastasis + LVI + SMAD4 + Adjuvant therapy | 0.19784561 | 0.199558697 | 0.006621522 |
| 3 | Rad-score + ΔCA19-9 + Lymph node metastasis + LVI + SMAD4 + Adjuvant therapy | 0.198989105 | 0.194932359 | 0.01124786 |
| 4 | Rad-score + ΔCA19-9 + Differentiation + LVI + SMAD4 + Adjuvant therapy | 0.19977719 | 0.191743931 | 0.014436288 |
| 5 | Rad-score + Differentiation + Lymph node metastasis + LVI + SMAD4 + Adjuvant therapy | 0.222610612 | 0.099364758 | 0.106815461 |
| 6 | Rad-score + ΔCA19-9 + Differentiation + Lymph node metastasis + SMAD4 + Adjuvant therapy | 0.200846238 | 0.187418792 | 0.018761427 |
| 7 | Rad-score + ΔCA19-9 + Differentiation + Lymph node metastasis + Adjuvant therapy | 0.19950763 | 0.192834516 | 0.013345703 |
| 8 | Rad-score + ΔCA19-9 + Differentiation + Lymph node metastasis + LVI | 0.200743146 | 0.187835881 | 0.018344337 |
ΔCA19-9 indicates a level decrease ≥80%; SMAD4 indicates a negative status; and the duration of adjuvant therapy was divided into three categories: ＜two cycles, two to four cycles, and four to six cycles.